Abstract
ABSTRACTStem cells are extraordinary cells with a unique ability of self-renewal and differentiation into various cell types such as muscle, nerve, bone, and blood cells. Historically, they have found significant applications in the biotech and pharma sectors. To grow and maintain stem cells artificially, researchers use basal media formulations supplemented with nutrients and growth factors, with Fetal bovine serum (FBS) as the key component of the culture medium. However, to maintain this supply every year, millions of pregnant cows are slaughtered for preparing FBS. The process of harvesting FBS also raises concerns about contamination with pathogens, animal proteins that may interfere with cellular behavior and ethical considerations regarding animal welfare. To overcome these limitations, here we report ClearX9-Stem™ - an affordable, sustainable, effective, and ethical replacement for an FBS-enriched stem cell culture medium. A specialized ClearX9-Stem™ cell culture medium formulation was designed to grow chicken embryonic fibroblast (SL-29) in the absence of FBS. Based on the results obtained, ClearX9-Stem™ is undergoing further refinement to meet the growing academic and industrial demand for serum-free culture media formulations. In the future, there is a need to customize and optimize ClearX9-Stem™ for the scalable growth of cells in bioreactors.HIGHLIGHTSClearX9-Stem™ provides good nutritional support for the growth of chicken embryonic fibroblast cells.ClearX9-Stem™ cell growth performance is comparable to the serum-enriched culture mediumClearX9-Stem™ maintains a healthy morphological profile of cells during divisionClearX9-Stem™ generates a stress-free environment within cellsClearX9-Stem™ does not require animal slaughter and reduces the environmental footprintClearX9-Stem™ has applications in the biotechnology, pharma, and cell-cultivated meat industries
Publisher
Cold Spring Harbor Laboratory
Reference14 articles.
1. Bouchie, A. (2002). Tissue engineering firms go under. Nat. Biotechnol. 20.
2. Bouchie, A. (2003). Industry ponders reimbursement crisis. Nat. Biotechnol. 21.
3. Caplan, A.I. , and Bruder, S.P. (2001). Mesenchymal stem cells: Building blocks for molecular medicine in the 21st century. Trends Mol. Med. 7.
4. Crowley, L.C. , Marfell, B.J. , Christensen, M.E. , and Waterhouse, N.J. (2016). Measuring cell death by trypan blue uptake and light microscopy. Cold Spring Harb. Protoc. 2016.
5. Culture, C. , Market, M. , Analysis, T. , By, R. , Application, B. , End-user, B. , and Region, B. (2023). Report Overview. 1–14.